Hematology, Oncology CME/CE Credits

Oncology/Hematology CE Courses – Update

myCMEYour search for high-quality, complimentary CME/CE stops right here. The courses below are presented by myCME, the continuing education engine in Haymarket Medical Network’s (HMN) expanding portfolio of clinical websites. Below you’ll find practice-relevant courses that carry valuable CME/CE credit. Simply click any link to get started earning credit on myCME.


Featured CE Courses

New Therapeutic Options in AML: An Update for Community Clinicians

Updates in AML for Community Clinicians | myCME

AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s)
Have you heard about the latest clinical advances in AML therapy? Join Drs Strickland and Wang as they discuss recent science that provides guidance for the care team on the use of newly approved and novel strategies for AML management.
Hematology Consults: Current Landscape of GVHD – Module 1

Hematology Consults: Current Landscape of GVHD – Module 1 | myCME

AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s)
Allogeneic hematopoietic stem-cell transplantation (alloHSCT) is favored for treating patients with acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndromes. AlloHSCTs rely on the immunoreactivity of the donor graft for a potent antitumor response, however, alloHSCTs are associated with acute and chronic graft versus host disease (GVHD), which can affect many different organs and tissues.
Hematology Consults: Acute & Chronic GVHD – Module 2

Hematology Consults: Acute & Chronic GVHD – Module 2 | myCME

AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s)
There is little guidance about choosing the most appropriate therapy for patients with graft vs host disease (GVHD) after undergoing an allogeneic hematopoietic stem cell transplantation (alloHSCT). Until the recently, steroids were the only agents with proven ability to treat patients with GVHD.
Targeted Treatments for Urothelial Cancer

Targeted Treatments for Urothelial Cancer

AMA PRA Category 1 Credit(s)TM, ANCC Contact Hour(s), AANP Contact Hour(s)
This activity will help advanced practitioners who treat patients with UC to know how to select and sequence these treatments.
Disparities and Improving the Care of Advanced HCC in the Hispanic Community

Disparities and Improving the Care of Advanced HCC in the Hispanic Community | myCME

AMA PRA Category 1 Credit(s)TM, ANCC Contact Hour(s)
Significant race and ethnicity-specific disparities in HCC care account in many respects for the increased incidence—approximately 36%—of HCC among Hispanics, who are more likely to present late and less likely to receive any HCC-directed treatment. However, improved screening and surveillance guidelines and greater understanding of the pathophysiology and molecular pathways in HCC has led to the emergence of targeted treatment.
Immunotherapy for the Treatment of Melanoma and Lung Cancer

Immunotherapy for the Treatment of Melanoma and Lung Cancer | myCME

CNE Contact Hour(s)
This program will outline the necessary and unique skill sets of the nurse navigator; which includes a thorough knowledge of lung cancer and melanoma biology, treatments, and treatment side effects; the ability to address psychosocial issues; and expertise in accessing and navigating the healthcare system on behalf of their patients.
The Role of Maintenance Therapy in AML

The Role of Maintenance Therapy in AML | myCME

AMA PRA Category 1 Credit(s)TM, ANCC Contact Hour(s), CE for Pharmacists
As the research of maintenance strategies in acute myeloid leukemia (AML) advances, it is important for clinicians stay abreast of study designs and results from clinical trials. This activity will discuss a patient case study and explain treatment decisions and rationale for maintenance strategies in AML.

Click for Oncology More Courses

Next post in CE Courses